Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Average (2018 - 2025)

Historic Equity Average for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Q3 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Equity Average rose 3485.83% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 3485.83%. This contributed to the annual value of $932.0 million for FY2024, which is 11789.07% up from last year.
  • Crinetics Pharmaceuticals' Equity Average amounted to $1.1 billion in Q3 2025, which was up 3485.83% from $1.2 billion recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Equity Average's 5-year high stood at $1.3 billion during Q1 2025, with a 5-year trough of $159.2 million in Q1 2021.
  • In the last 5 years, Crinetics Pharmaceuticals' Equity Average had a median value of $368.8 million in 2022 and averaged $566.5 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Equity Average plummeted by 2245.52% in 2023 and then skyrocketed by 21915.22% in 2024.
  • Crinetics Pharmaceuticals' Equity Average (Quarter) stood at $262.8 million in 2021, then rose by 27.05% to $333.8 million in 2022, then soared by 62.78% to $543.4 million in 2023, then skyrocketed by 98.53% to $1.1 billion in 2024, then grew by 3.98% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.3 billion during Q1 2025.